About AVANT Immunotherapeutics
Avant develops and markets vaccines for underserved markets. The company is developing a broad portfolio of vaccines addressing a wide range of applications including bacterial and viral diseases, cardiovascular diseases, biodefense and food safety.
Missing: AVANT Immunotherapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AVANT Immunotherapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing AVANT Immunotherapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AVANT Immunotherapeutics is included in 1 Expert Collection, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
AVANT Immunotherapeutics Frequently Asked Questions (FAQ)
When was AVANT Immunotherapeutics founded?
AVANT Immunotherapeutics was founded in 1983.
Where is AVANT Immunotherapeutics's headquarters?
AVANT Immunotherapeutics's headquarters is located at 119 Fourth Avenue, Needham.
What is AVANT Immunotherapeutics's latest funding round?
AVANT Immunotherapeutics's latest funding round is Acquired.
How much did AVANT Immunotherapeutics raise?
AVANT Immunotherapeutics raised a total of $39.5M.
Who are the investors of AVANT Immunotherapeutics?
Investors of AVANT Immunotherapeutics include Celldex Therapeutics, Pfizer Venture Investments, LRG Capital Group, Clarion Capital Partners, RCM Capital Management and 10 more.
Who are AVANT Immunotherapeutics's competitors?
Competitors of AVANT Immunotherapeutics include BlueWillow Biologics, Bellicum Pharmaceuticals, Symphogen, Embera NeuroTherapeutics, Prevtec Microbia and 13 more.
Compare AVANT Immunotherapeutics to Competitors
The focus of Savine Therapeutics is to develop and commercialise vaccines for prevention and treatment of diseases using it's Scrambled Antigen Vaccine (SAVINE) technology. The technology was invented by researchers in the John Curtin School of Medical Research at the Australian National University. Per the company, it enables production of vaccines suitable for a broad range of serious worldwide infectious diseases and cancers. See www.savine.com
BlueWillow Biologics develops nasal vaccines and immunotherapy to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. The company's novel intranasal NanoVax adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. BlueWillow Biologics was formerly known as NanoBio. The company was founded in 1999 and is based in Ann Arbor, Michigan.
Lux Biosciences is a clinical stage biotechnology company specializing in the development and commercialization of medications for serious ophthalmic diseases. With a product in NDA/MAA submission stage and several earlier-stage projects, Lux is building a high-growth, and sustainable ophthalmic company.
NAICONS (New Anti-Infective CONSortium) is a new organization aiming at integrating resources in the field of infectious diseases to create a strategic and operative hub dedicated to discover and develop antibiotics targeting unmet medical needs.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Phrixus Pharmaceuticals is developing Carmeseal (poloxamer 188 or P188) for Duchenne muscular dystrophy and acute decompensated heart failure. Carmeseal has been shown to improve the efficiency of damaged hearts to pump blood and to improve the performance of damaged diaphragms. When Carmeseal, which acts as a molecular band-aid, is infused into the bloodstream, it encounters and binds to microscopic tears in the muscle. This prevents the pathological leak of calcium into the cells, which causes calcium overload and keeps the muscle from performing as required. Carmeseal, which has been shown to be effective in four animal models of DMD and heart failure, is expected to have its effect in patients with DMD irrespective of the genetic defect that causes the disease.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.